Three cases of substitution errors leading to hyoscine hydrobromide overdose

Clinical Toxicology

Volumn 43, Issue 7, 2005, Pages 861-865

  Van Sassenbroeck, Diederik ^a   Hemelsoet, Dimitri ^a   Vanwalleghem, Phyllis ^a   Verstraete, Alain ^a   Santens, Patrick ^a   Monsieurs, Koenraad ^a   Buylaert, Walter ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anticholinergic; Dispensing error; Hyoscine butylbromide; Hyoscine hydrobromide; Pharmacy; Scopolamine

Indexed keywords

ACTIVATED CARBON; SCOPOLAMINE BROMIDE; SCOPOLAMINE BUTYL BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ADULT; ANTICHOLINERGIC TOXIC SYNDROME; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG SUBSTITUTION; DRY SKIN; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; MALE; MEDICATION ERROR; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL HEALTH; MENTAL INSTABILITY; MYDRIASIS; PHARMACIST; PHONOPHOBIA; PHOTOPHOBIA; TACHYCARDIA; TREMOR; INTOXICATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; FEMALE; HUMANS; MALE; MEDICATION ERRORS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; OVERDOSE; SCOPOLAMINE; TREATMENT OUTCOME;

EID: 33644847207     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650500357560     Document Type: Article

References (30)

1. Chua S-S, Wong ICK, Edmondson H, Allen C, Chow J, Peacham J, Hill G, Grantham J. A feasibility study for recording of dispensing errors and 'near misses' in four UK primary care pharmacies. Drug Safety 2003; 26:803-813.
2. Seifert SA, Jacobitz K. Pharmacy prescription dispensing errors reported to a regional poison control centre. J Toxicol, Clin Toxicol 2002; 40:919-923.
3. Oertel R, Richter K, Ebert U, Kirch W. Determination of scopolamine in human serum and microdialysis samples by chromatography-tandem mass spectrometry. J Chromatogr, B 2001; 750:121-128.
4. Grasha AF, Schell K. Psychosocial factors, workload, and human error in a simulated pharmacy dispensing task. Percept Mot Skills 2001; 92:53-71.
5. Antimuscarinics/antispasmodics. In: McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2001:1180-1211.
6. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 1998; 38:720-726.
7. Dahl E, Offer-Ohlsen D, Lillevold PE, Sandvik L. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984; 36:116-120.
8. Kanto J, Kentala E, Kaila T, Pihlajamäki K. Pharmacokinetics of scopolamine during caesarean section: relationship between serum concentration and effect. Acta Anaesthesiol Scand 1989; 33:482-486.
9. Anderson S, McGuire R, McKeown D. Comparison of the cognitive effects of premedication with hyoscine and atropine. Br J Anaesth 1985; 57:169-173.
10. Wick H. Enteral absorption of hyoscine N-butylbromide. J Pharm Pharmacol 1967; 19:779.
11. 14C]hyoscine N-butylbromide (butylscopolamine). J Pharm Pharmacol 1975; 27:542-543.
12. Pomeroy AR, Rand MJ. Anticholinergic effects and passage through the intestinal wall of N-butylhyoscine bromide. J Pharm Pharmacol 1969; 21:180-187.
13. Rupreht J. Hyoscine derivative in children - but was it hyoscine? Anaesthesia 1991; 46:514.
14. 3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000; 50:61-64.
15. Sissons GRJ, McQueenie A, Mantle M. The ocular effects of hyoscine-n-butylbromide ("buscopan") in radiological practice. Br J Radiol 1991; 64:584-586.
16. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. BMJ 1979; 1:376-378.
17. Nachum Z, Shahal B, Shupak A, Spitzer O, Gonen A, Beiran I, Lavon H, Eynan M, Dachir S, Levy A. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001; 296:121-123.
18. Kentala E, Kaila T, Arola M, Matilla M, Kanto J. Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. Eur J Anaesth 1991; 8:135-140.
19. Tilleul P, Mons B, Schmitt C, Lamorte JM, Begue D. Intravenous drug preparation practices: a survey in a French university hospital. Pharm World Sci 2003; 25:276-279.
20. Catterson ML, Martin RL. Anticholinergic toxicity masquerading as neuroleptic malignant syndrome: a case report and review. Ann Clin Psychiatry 1994; 6:267-269.
21. Lauwers LF, Daelemans R, Baute L, Verbraeken H. Scopolamine intoxications. Intensive Care Med 1983; 9:283-285.
22. Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med 1998; 16:505-507.
23. Osterholm RK, Camoriano JK. Transdermal scopolamine psychosis. JAMA 1982; 247:3081.
24. Rodysill KJ, Warren JB. Transdermal scopolamine and toxic psychosis. Ann Intern Med 1983; 98:561.
25. Perrone J, Shaw L, De Roos F. Laboratory confirmation of scopolamine co-intoxication in patients using tainted heroin. J Toxicol, Clin Toxicol 1999; 37:491-946.
26. Kumar CM. Unattended continuous infusion of hyoscine leading to delayed visual disturbances. Can J Anaesth 1994; 41:551.
27. Danks JL. Hyoscine derivatives in children. Anaesthesia 1990; 45:1089.
28. Muttray A, Maier W, Vogt T, Demuth W, Konietzko J. Enzephalopathie nach intoxication mit einem anticholinergicum. Dtsch Med Wochenschr 1994; 119:731.
29. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349:2274-2275.
30. Buylaert W, Van Sassenbroeck D, Verstraete A, Hemelsoet D, Monsieurs K. A pharmacy dispensing error leading to hyoscine hydrobromide overdoses. Br J Clin Pharmacol 2005; 59:123-124.